Delpor Advances Pipeline to Include Spasticity Maintenance Therapy with $2.5 Million NIH Grant for Tizanidine Implant

Company expects to enter clinic by 2023 and if approved, Delpor’s tizanidine implant will be the first minimally invasive, long-acting therapy for the maintenance of moderate to severe spasticity Expanded [...]

November 16th, 2021|

Delpor Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Once-Yearly Risperidone Implant

If approved, Delpor’s risperidone implant will be the first once-yearly schizophrenia maintenance therapy. BRISBANE, CA, April 22, 2021 — Delpor, Inc. (Delpor), a clinical-stage biopharmaceutical company that utilizes innovative technologies [...]

April 22nd, 2021|

Delpor to Tackle Opioid Use Disorder with $5.7 million NIH HEAL Grant Award for the Development of a Once-Yearly Naltrexone Therapy to Prevent Relapses

Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may [...]

October 9th, 2019|
Go to Top